Mutual of America Capital Management LLC grew its stake in shares of Halyard Health Inc (NYSE:HYH) by 3.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 39,443 shares of the medical instruments supplier’s stock after purchasing an additional 1,462 shares during the period. Mutual of America Capital Management LLC owned about 0.08% of Halyard Health worth $1,821,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently made changes to their positions in HYH. Jarislowsky Fraser Ltd purchased a new stake in shares of Halyard Health during the third quarter valued at $200,000. QS Investors LLC raised its position in Halyard Health by 305.6% during the second quarter. QS Investors LLC now owns 5,176 shares of the medical instruments supplier’s stock valued at $203,000 after buying an additional 3,900 shares during the period. Quotient Investors LLC acquired a new position in Halyard Health during the third quarter valued at $203,000. Jane Street Group LLC acquired a new position in Halyard Health during the third quarter valued at $211,000. Finally, Raymond James Financial Services Advisors Inc. acquired a new position in Halyard Health during the second quarter valued at $217,000. 90.05% of the stock is owned by institutional investors and hedge funds.
Shares of Halyard Health Inc (HYH) traded up $1.08 during mid-day trading on Wednesday, reaching $47.96. The company’s stock had a trading volume of 62,168 shares, compared to its average volume of 298,165. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.19 and a current ratio of 2.13. Halyard Health Inc has a 12 month low of $35.24 and a 12 month high of $50.99. The firm has a market cap of $2,225.20, a price-to-earnings ratio of 39.39, a P/E/G ratio of 2.49 and a beta of 1.71.
Several research analysts recently weighed in on the company. TheStreet raised Halyard Health from a “c+” rating to a “b” rating in a research report on Monday, December 4th. Zacks Investment Research lowered Halyard Health from a “buy” rating to a “hold” rating in a research report on Thursday, February 1st. ValuEngine raised Halyard Health from a “hold” rating to a “buy” rating in a research report on Sunday, December 31st. Finally, Stifel Nicolaus reissued a “buy” rating and set a $52.00 price target on shares of Halyard Health in a research report on Friday, November 3rd. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $49.00.
Halyard Health Profile
Halyard Health, Inc is a medical technology company. The Company operates through two segments: Medical Devices and Surgical and Infection Prevention (S&IP). The Medical Devices segment provides a portfolio of product offerings focused on pain management, respiratory and digestive health. The S&IP segment provides healthcare supplies and solutions that target the prevention of healthcare-associated infections.
Receive News & Ratings for Halyard Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health and related companies with MarketBeat.com's FREE daily email newsletter.